Facebook
Twitter
LinkedIn
Forward17th Annual Cardiometabolic Health Congress On-Demand
Hundreds of practitioners gathered in Boston in October 2022 for the annual conference from Cardiometabolic Health Congress (CMHC).
Category
- CMHC
Format
- Conference / meeting
- Video
Credits
- ABIM MOC and AMA PRA Category 1 Credit™
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
Virtual Symposium - Optimizing Lipid Lowering Therapy in Women: Gaps, Perspectives, and Advances
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally.
Category
- CMHC
Format
- Video
Credits
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
Virtual Symposium - Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk: Emerging Evidence, Evolving Guidance, and Expert Perspectives
GLP-1 RAs have carved an important role in the management of patients with type 2 diabetes (T2D), not only in glycemic control, but also in reducing cardiovascular and renal risk.
Category
- CMHC
Format
- Video
Credits
- ABIM MOC and AMA PRA Category 1 Credit™
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
Virtual Symposium - Escaping the Current Gaps in the Understanding and Treatment of CKD Anemia: Making Sense of Emerging Therapies
Anemia is a common comorbidity in patients with chronic kidney disease (CKD), and is associated with significant morbidity and impacts on quality of life. The complicated pathophysiology of the condition and the disadvantages associated with current treatments are some of the major barriers that
Category
- CMHC
Format
- Video
Credits
- ABIM MOC and AMA PRA Category 1 Credit™
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis & Treatment
The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with this condition.
Category
- CMHC
Format
- Self-study / Enduring
Credits
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
Screening & Treatment of Pompe Disease: Clinical Advances in a Changing Landscape
How rare is a rare disease?While the number of people affected by an individual rare disease may be small, the total number of people with a rare diseases—an estimated 25 to 30 million in the United States—is enormous!
Category
Format
Credits
- ACCME (All Other)
- ACCME (MD/DO Only)
- ACPE Pharmacy
- ANCC
Virtual Symposium: What You Need to Know About Optimizing Cardiorenal Outcomes with Novel NonSteroidal MRAs
During this recorded symposium from the 2022 American Heart Association (AHA), you will get a chance to:
Category
- CMHC
Format
- Video
Credits
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- Participation
Clinical Brief: Why Should We Use CGM in Patients With Type 2 Diabetes? Assessing the Evidence and Practical Pearls for Integration
This clinical brief was developed from a presentation at the 17th annual CMHC Annual Congress held from October 19-22, 2022 in Boston, MA. The session, “Why Should We Use CGM in Patients With Type 2 Diabetes?
Category
- CMHC
Format
- Monograph
Credits
- ABIM MOC and AMA PRA Category 1 Credit™
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation
Primer: Gamechangers in Alopecia Areata: Targeted Therapies for Patient-Centered Care
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice.
Category
- LivDerm
- TME
Format
- Webinar recorded
Credits
- AMA PRA Category 1 Credit™
- ANCC
- Participation
Making Sense of LDL-C Combination Therapy in 2022: Strategies and Pearls to Move Beyond Inertia to Improve Patient Outcomes
Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events. Even with the advances in LDL-C lowering therapy, LDL-C goal achievement is low, and clinical inertia and patient non-adherence are major factors for continued ASCVD residual risk. The la
Category
- CMHC
Format
- Self-study / Enduring
Credits
- ABIM MOC and AMA PRA Category 1 Credit™
- ACPE Pharmacy
- AMA PRA Category 1 Credit™
- ANCC
- CDE
- Participation